All In Biotech

Drug Trial Radar · NCT05293171

Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects

A Single-Dose, Randomized, Double-Blind, Placebo-Controlled, Positive-Controlled, Four-Way Crossover Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Mar 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

38

Actual

Start

Jun 11, 2021

Primary completion

Jun 1, 2022

Study completion Aug 15, 2022

Sponsor

Lead sponsor
BioLineRx, Ltd.Industry
Sponsor type
Industry
Collaborators
Celerion
First posted
Mar 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, care provider, investigator)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study will assess the corrected QT (QTc) effects (electrocardiogram \[ECG\]) of motixafortide (BL-8040) 1.25 mg/kg (therapeutic dose) and 2 mg/kg (supratherapeutic dose) following a single subcutaneous (SC) injection relative to placebo in approximately 40 healthy subjects.

Conditions

  • Healthy Subjects

Interventions

  • 1.25 mg/kg BL-8040 + BL-8040-matching placeboDrug

    Administered via subcutaneous (SC) injection

  • 2 mg/kg BL-8040Drug

    Administered via subcutaneous (SC) injection

  • BL-8040-matching placeboDrug

    Administered subcutaneous (SC) injection

  • 400 mg Moxifloxacin (1x400 mg tablet)Drug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. QTc Effect of Single Subcutaneous (SC) Injections of Motixafortide (BL-8040) 1.25 mg/kg and 2 mg/kgTime frame: Cardiodynamic ECG recordings on Day 1 (day of dosing) at different time points prior to dosing and up to 24 hours post-dose in each period (each period is 24 hours long, a total of 4 periods)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Celerion

    Phoenix, Arizona

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.